EMERGEX VACCINES
Emergex Vaccines offer affordable, practical and effective vaccines on-demand, which are suited to low resource environments, disproportionately affected by pandemics. These vaccines will be used to create a clinical grade international vaccine repository that will act as a first line of defence in the case of existing and newly emerging infectious disease outbreaks.
EMERGEX VACCINES
Industry:
Biopharma Biotechnology Health Care
Founded:
2016-01-01
Address:
Abingdon, Oxfordshire, United Kingdom
Country:
United Kingdom
Website Url:
http://www.emergexvaccines.com
Total Employee:
1+
Status:
Active
Total Funding:
12.99 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics Google Tag Manager WordPress Google Universal Analytics Domain Not Resolving Apache
Current Employees Featured
Founder
Investors List
Department of Health and Social Care (DHSC)
Department of Health and Social Care (DHSC) investment in Grant - Emergex Vaccines
Vickers Venture Partners
Vickers Venture Partners investment in Series A - Emergex Vaccines
Innovate UK
Innovate UK investment in Grant - Emergex Vaccines
Trend Investment Group
Trend Investment Group investment in Seed Round - Emergex Vaccines
Official Site Inspections
http://www.emergexvaccines.com Semrush global rank: 3.51 M Semrush visits lastest month: 4.21 K
Unable to get host informations!!!
More informations about "Emergex Vaccines"
Home - Gylden Pharma
We work on addressing some of the world’s most impactful health threats with a growing pipeline of candidates. Gylden’s T cell-priming vaccine and immunotherapy candidates combine core proprietary technologies.First …See details»
Emergex Vaccines - Crunchbase Company Profile
Emergex Vaccines may be growing as evidenced by a series of recent developments. The company has secured a contract worth £1.79 million with …See details»
Emergex Vaccines Information - RocketReach
Emergex, a clinical-stage, privately-held biotechnology company headquartered in Abingdon, UK, with an operating subsidiary in Doylestown, Pennsylvania, USA, is pioneering the …See details»
EMERGEX VACCINES HOLDING LIMITED – Funding, Valuation, …
Oct 17, 2024 Emergex, a UK-based biotechnology company headquartered in Abingdon, UK, is pioneering the development of T-Cell Priming vaccines to address some of the world's most …See details»
Emergex Vaccines Company Profile | Management and Employees …
Www.emergexvaccines.com . Emergex Vaccines Profile and History. Emergex Vaccines Holding Limited is a biotechnology company focused on the development of vaccines against viral and …See details»
Emergex Vaccines - EU-Startups
Mar 4, 2022 Emergex focuses on developing vaccines that prevent virulent diseases such as Zika, Dengue Fever, Ebola and even pandemic Flu. The company’s set-point vaccines deliver …See details»
EMERGEX VACCINES LIMITED - Companies House
Jan 28, 2025 EMERGEX VACCINES LIMITED - Free company information from Companies House including registered office address, filing history, accounts, annual return, officers, …See details»
EMERGEX VACCINES LTD | Startup Profile and Investments
Emergex Vaccines is a pioneering UK biotechnology company that focuses on developing T cell-priming immune set-point candidates to combat infectious diseases. Founded in 2016, the …See details»
Company Spotlight: Emergex Vaccines | Milton Park
Jan 18, 2022 We recently caught up with Emergex Vaccines, eager to learn more about the company’s work developing a special kind of vaccine which could reduce regular booster jabs …See details»
Emergex Announces Company Name Change to “Gylden Pharma …
Oct 17, 2024 Abingdon, United Kingdom, 17 October 2024 – Emergex Vaccines Holding Limited, a clinical-stage biotechnology company that is addressing major global infectious …See details»
Emergex announces approval to initiate Phase I clinical
Nov 15, 2021 Email: [email protected] Robin Cohen, Chief Commercial Officer Phone: +44 (0) 1235 527589 Email: [email protected]: Chris Gardner / Ashley Tapp / …See details»
Emergex Vaccines Forms US Subsidiary (Emergex USA) by …
Sep 1, 2020 At the Company Emergex Storme Moore-Thornicroft, Executive Director Phone: +44 (0) 1235 527589 Email: [email protected] Consilium Strategic Communications …See details»
Emergex Vaccines | VentureRadar
Emergex Vaccines is a clinical-stage, privately held biotechnology company headquartered near Oxford, UK, with R&D facilities in Milton Park, UK and... ... Find out ...See details»
Emergex announces approval to initiate Phase I clinical trial of its ...
Nov 15, 2021 Emergex Vaccines Holding Limited (‘Emergex’, or ‘the Company’), a company tackling major global infectious disease threats through the development of 100% synthetic T …See details»
Series A - Emergex Vaccines - 2020-01-09 - Crunchbase
Jan 9, 2020 Organization Name . Emergex Vaccines . Announced Date Jan 9, 2020; Funding Type Series A; Funding Stage Early Stage Venture; Money Raised . obfuscated. obfuscated. …See details»
Emergex Vaccines - VentureRadar
Emergex Vaccines is a clinical-stage, privately held biotechnology company headquartered near Oxford, UK, with R&D facilities in Milton Park, UK and... ... Find out ...See details»
Emergex Vaccines forms US subsidiary (Emergex USA) by …
Sep 1, 2020 Acquisition brings critical technical pre-clinical vaccine development capabilities in-house and establishes US based Emergex subsidiary Emergex uniquely develops novel 100% …See details»
Emergex T Cell-Priming Vaccine Candidate for Betacoronaviruses …
Oct 2, 2024 - NIAID will be conducting and sponsoring clinical trials to accelerate and to streamline the rapid development of next-generation COVID-19 vaccines. ABINGDON, United …See details»
Emergex Vaccines Forms US Subsidiary (Emergex USA) by
Sep 1, 2020 At the Company Emergex Storme Moore-Thornicroft, Executive Director Phone: +44 (0) 1235 527589 Email: [email protected] Consilium Strategic Communications …See details»
Emergex confirms its next generation T-Cell Priming COVID-19 …
Dec 1, 2021 About Emergex . Emergex, a biotechnology company headquartered in Abingdon, UK, with an operating subsidiary in Doylestown, Pennsylvania, USA, is pioneering the …See details»